Kornimate/medical-research-clean huggingface dataset:
pleuroscopy first versus thoracentesis first in patients with suspected malignant pleural effusions

Conditions: Pleural Effusion; Cancer

Summary: this is a randomized control trial of patients with suspected malignant pleural effusions to compare whether patients who have a thoracentesis or pleuroscopy (pleural biopsy) obtain an adequate biopsy, achieve a diagnosis, and begin cancer-directed therapy faster.

this is a randomized control trial of patients with suspected malignant pleural effusions comparing patients who undergo either pleuroscopy or thoracentesis as the first diagnostic test. both procedures are considered standard of care for this diagnosis but it is unknown which one provides more adequate biopsy samples and achieves faster diagnosis and shorter time to oncologic treatment. currently, most patients undergo thoracentesis first and, if this is inadequate for diagnosis, they then undergo pleuroscopy for further biopsy samples. this study seeks to assess whether patients who undergo pleuroscopy as the first test obtain adequate biopsy samples and a faster path to further oncologic care compared to patients who undergo thoracentesis first. patients will be recruited and randomized in a 1:1 manner. ultrasound is routinely used prior to the procedure and a chest x-ray is done after the procedure. any other imaging will be determined by clinic need only. no imaging will be done for research purposes. no additional samples will be collected other than what is necessary for diagnostic purposes. in patients who have a non-diagnostic thoracentesis, the participants will be referred for pleuroscopy as the next diagnostic step. in the rare case that pleuroscopy does not achieve adequate diagnosis, the next step would be a liquid biopsy (non-invasive serologic testing for oncologic markers.) the need for liquid biopsy in participants in this study will be determined on a case-by-case basis depending on the clinical concern for malignancy.

Eligibility criteria:
inclusion criteria: * referral for diagnostic pleural procedure. * age ≥ 18 years. * suspected malignant pleural effusion (suggestive radiologic appearance (based on computed tomography or positron emission tomography) or suspected cancer with associated effusion.) exclusion criteria: * inability to provide informed consent. * needs emergent drainage. * pleural effusion is known to be malignant. * suspected transudative, infectious or inflammatory effusion etiology. * having prior inconclusive/non-diagnostic thoracentesis or pleuroscopy. * patient is deemed by the clinical team to be more appropriate for vats biopsy. * terminally ill patients in whom a diagnosis will not change management, or who is unlikely to be a candidate for oncological treatment due to significant comorbidities. * pregnancy
working ivf patients' quality of life

Conditions: In Vitro Fertilization (IVF); Infertility

Summary: infertility affects approximately 1 in 6 couples and may require the use of medically assisted reproduction techniques. in france, there were more than 60,000 in vitro fertilization (ivf) attempts in 2016. the burden of the ivf process is even more significant for working women, causing significant absenteeism due to medical appointments but also to the psychological discomfort caused by the management. unfortunately, there are no studies that specifically address the quality of life of working women undergoing ivf. the cohort project aims to measure quality of life using validated questionnaires (fertiqol, stai anxiety scale and bdi depression inventory) in active patients who are scheduled for a first ivf attempt. quality of life will be measured before starting treatment and at embryo transfer and will be followed up at each embryo transfer for a maximum period of 18 months. the follow-up will end after the live birth of a child or at the end of the 18 months of follow-up. the investigators will also evaluate, by means of a specific questionnaire, the satisfaction with the interactions between professional and private life (management and consequences of absenteeism at work, consequences on professional evolution, anxious repercussions in the professional and private domains) in the active women undergoing ivf treatment.


Eligibility criteria:
inclusion criteria: * professionally active women aged 18 to 42 years * beginning in vitro fertilization treatment at the montpellier university hospital exclusion criteria: * women who have already had an ivf attempt in the process of egg donation or pre-implantation diagnosis * history of psychotic or dissociative disorder * not fluent in french * not affiliated to a social security system * protected by law or under curators/guardianship * no record of non-objection to participate in the study

Keywords: infertility assisted reproductive techniques quality of life work personal and professional interactions depression
analysis of driver gene mutation in early stage non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: analysis of driver gene variation in early stage non-small cell lung cancer

fluorescence quantitative polymerase chain reaction (pcr) was used to detect the variation of driver gene in regional lymph nodes of early stage non-small cell lung cancer (nsclc), and to analyze the relationship between the variation and disease recurrence and survival prognosis. evaluate the effect of the variation of driving gene in lymph nodes of early stage nsclc on prognosis, identify the high-risk factors that promote the recurrence and metastasis of early stage tumor. so as to improve the diagnosis and treatment path of lung cancer, provide important pathological basis for the clinical diagnosis and treatment of early stage non-small cell lung cancer, enable patients to receive more accurate treatment, and improve their survival prognosis.

Eligibility criteria:
inclusion criteria: 1. female or male, 18 years of age or older 2. histologically or cytologically proven diagnosis of early stage nsclc 3. the lesion was completely resected by radical surgery 4. able to get tumor tissue sample 5. complete information of clinicopathological , survival, recurrence and metastasis can be obtained through follow-up exclusion criteria: 1. combine with other tumor type 2. the investigator judges the situation that may affect the clinical search process and results

Keywords: regional lymph nodes molecular metastasis driver gene mutation
safety and tolerability study of nbi-98854 for the treatment of tardive dyskinesia

Conditions: Tardive Dyskinesia

Summary: phase 3, open-label, study to evaluate the safety and tolerability of nbi-98854 administered once daily (qd) for a total of 48 weeks of treatment. this study will enroll approximately 150 medically stable male and female subjects with clinical diagnoses of schizophrenia or schizoaffective disorder with neuroleptic-induced td or mood disorder with neuroleptic-induced td.


Eligibility criteria:
inclusion criteria: 1. subjects of childbearing potential must agree to use hormonal or two forms of nonhormonal contraception (dual contraception) consistently during the screening, treatment and follow-up periods of the study. 2. female subjects must not be pregnant. 3. have one of the following clinical diagnoses for at least 3 months prior to screening: schizophrenia or schizoaffective disorder, or mood disorder 4. have a clinical diagnosis of neuroleptic-induced td for at least 3 months prior to screening. 5. have moderate or severe td 6. if using maintenance medication(s) for schizophrenia or schizoaffective disorder, or mood disorder, be on stable doses. 7. be in general good health. 8. have adequate hearing, vision, and language skills to perform the procedures specified in the protocol. 9. have a negative urine drug screen for amphetamines, barbiturates, benzodiazepine, phencyclidine, cocaine, opiates, or cannabinoids. exclusion criteria 1. have an active, clinically significant unstable medical condition within 1 month prior to screening. 2. have a known history of substance dependence, substance (drug) or alcohol abuse. 3. have a significant risk of suicidal or violent behavior. 4. have a known history of neuroleptic malignant syndrome. 5. have a known history of long qt syndrome or cardiac tachy-arrhythmia. 6. have a cancer diagnosis within 3 years prior to screening (some exceptions allowed). 7. have received an investigational drug within 30 days before screening or plan to use an investigational drug (other than nbi-98854) during the study. 8. have a blood loss ≥550 ml or donated blood within 30 days prior to baseline. 9. have an allergy, hypersensitivity, or intolerance to tetrabenazine. 10. are currently pregnant or breastfeeding.
visual and auditory breathing-swallowing coordinated training

Conditions: Breathing-Swallowing Coordination; Dysphagia Rehabilitation

Summary: dysphagia is caused by multiple factors, and respiratory-swallowing discoordination is considered to be one of the factors. the investigators recently developed a visual and auditory breathing-swallowing coordinated training device. in this study, investigators examined the validity of a this device for healthy subjects. the investigators will examine which respiratory phase the swallowing occurs when the swallowing is started in accordance with the signal lighting and voice of this device.


Eligibility criteria:
inclusion criteria: * subjects with written informed consent to participate in the study exclusion criteria: * subjects with an apparent swallowing disorder * subjects with clinically evident cerebrovascular diseases
the dual impact of cirrhosis on transplantation for hepatocellular carcinoma：a two-center retrospective cohort study in china

Conditions: Hepatocellular Carcinoma; Cirrhosis

Summary: background: this study aims to investigate the correlation between cirrhosis and hepatocellular carcinoma (hcc) recurrence after liver transplantation. methods: the study retrospectively collected data enrolled from 519 hcc patients who underwent liver transplantation from two center(the first affiliated hospital, zhejiang university school of medicine and shulan (hangzhou) hospital, january 2015 to december 2020), based on important variables, 1:3 propensity score matching (psm) were performed respectively.


Eligibility criteria:
inclusion criteria: the patients undergoing liver transplantation for hcc from january 2015 to december 2020. exclusion criteria: re-transplantation or combined liver-kidney transplantation; incomplete laboratory or clinical data; death within 90 days.
food oral immunotherapy for peanut allergy

Conditions: Peanut Allergy

Summary: this is an open label observational single center study of clinical food oral immunotherapy outcomes with biomarker samples and participant and/or caregiver-completed questionnaires in participants between 6 months and 65 years of age with ige-mediated peanut allergy undergoing food oral immunotherapy.

in this research study the investigators want to learn more about the experience of participants with peanut allergy and their caregivers undergoing food oral immunotherapy (oit) for peanut allergy. food oral immunotherapy (oit) is a treatment for individuals with a food allergy to reduce the body's allergic response to the food allergen, resulting in fewer symptoms. the treatment is also called desensitization. an individual becomes desensitized to the food allergen by ingesting small amounts of the food that are slowly increased. over time, this helps the body's immune system become used to the food so that it no longer causes an allergic reaction. by desensitizing to peanut, it may lower the risk of life-threatening allergic reactions and cause a decreased sensitivity to peanut. the investigators specifically want to learn more about the effects of food oit on quality of life and other outcomes important to participants with peanut allergy and their caregivers and to ultimately develop tests to predict who may respond favorably to food oit.

Eligibility criteria:
inclusion criteria: * individuals between 6 months and 65 years of age with a diagnosis of immunoglobulin e (ige)-mediated peanut allergy and their caregivers; a diagnosis of ige-mediated peanut allergy is defined by: (1) documented history of peanut allergy or determined to be allergic by oral food challenge; (2) evidence of peanut-specific ige by either: positive skin prick test to peanut allergen (reaction wheal at least 3 mm larger than saline control) or serum peanut-specific ige \> 0.34 kilo-unit/liter (ku/l) or international unit/milliliter (iu/ml) at screening visit * referral by massachusetts general hospital (mgh) allergist for food oral immunotherapy * willing to sign informed consent or whose caregiver is willing to sign the informed consent (age appropriate) * willing to sign the assent form, if age appropriate exclusion criteria: * history of severe or life-threatening episode of anaphylaxis or anaphylactic shock within 60 days of screening * severe or poorly controlled asthma * diagnosis of other severe or complicating medical problems, including autoimmune or chronic immune inflammatory conditions or gastrointestinal inflammatory conditions, such as inflammatory bowel diseases and eosinophilic gastrointestinal disorders * current use of beta blocker medication(s) * inability to cooperate with and/or perform oral food challenge procedures * females who are pregnant, planning to become pregnant, or breastfeeding * investigator determination of safety concern for any reason

Keywords: food allergy
task shifting to treat depression and hiv medication nonadherence in low resource settings

Conditions: HIV Infections; Depression

Summary: a hybrid effectiveness-efficacy trial to evaluate a stepped care task shifted intervention to treat depression and hiv medication nonadherence in low resource settings in rural zimbabwe.

depression is commonly co-morbid with hiv infection in zimbabwe and is consistently associated with worse adherence to antiretroviral therapy (art). a task-shifted intervention for depression and art adherence, suitable for delivery by non-specialists, could make a critical difference to the health and survival of people managing the challenges of hiv treatment in zimbabwe. the tendai trial is a two-arm randomized controlled trial of an intervention for people on art with viral non-suppression and clinically significant depression. it will be delivered at an hiv clinic in marondera. tendai is a collaboration between the department of psychiatry, university of zimbabwe college of health sciences, king's college london institute of psychiatry, psychology and neuroscience (london uk), and the department of psychiatry at massachusetts general hospital / harvard medical school.

Eligibility criteria:
inclusion criteria: * initiated on art for at least 6 months * clinically significant depression symptoms scoring \>/= 10 on the patient health questionnaire-9 * viral non-suppression in past two months per local clinic standard (vl \> 1000 copies/ml) * able to provide informed consent * if prescribed antidepressants, on stable regimen for at least 2 months exclusion criteria: * unable to provide informed consent * active major mental illness (e.g. untreated psychosis or mania, actively suicidal), major untreated or undertreated mental illness or advanced physical disease or severe cognitive impairment assessed using the psychosis module of the mini, the phq-9, and the international hiv dementia scale which would interfere with engagement in pst-ad * has ever received pst or cbt for depression * less than 18 years of age

Keywords: hiv treatment depression medication adherence
a study of fresolimumab in patients with steroid-resistant primary focal segmental glomerulosclerosis (fsgs)

Conditions: Primary Focal Segmental Glomerulosclerosis

Summary: the primary objectives of this trial are as follows: * to compare the achievement of a partial remission (pr) or complete remission (cr) in urinary protein: creatinine ratio (up/c ratio) in patients treated with fresolimumab versus placebo * to compare the safety profile of patients treated with fresolimumab versus placebo the secondary objectives are as follows: * to compare the reduction in proteinuria in patients treated with fresolimumab versus placebo * to evaluate fresolimumab dose-dependent reduction in proteinuria * to compare the change in renal function (estimated glomerular filtration rate \[egfr\]) in patients treated with fresolimumab versus placebo * to evaluate the multiple-dose pharmacokinetics of fresolimumab


Eligibility criteria:
inclusion criteria: * the patient's renal biopsy is consistent with the diagnosis of primary focal segmental glomerulosclerosis (fsgs) including all histological subtypes. * the patient has an egfr ≥ 30 ml/min/1.73 m2 * the patient has a urinary total protein:creatinine ratio ≥ 3 mg protein/mg creatinine * in the opinion of the investigator, the patient has steroid-resistant fsgs. the patient must have been treated for fsgs with a course of high-dose steroid therapy for a minimum of 4 weeks * the patient has been treated with an acei (angiotensin converting enzyme inhibitor) and/or arb (angiotensin receptor blocker) at a stable dose for a minimum of 4 weeks prior to visit 2 (treatment start) exclusion criteria: * the patient has fsgs which in the investigator's opinion is secondary to another condition * the patient has been taking prednisone at a dose \> 10 mg/day (or equivalent dose of an alternative glucocorticoid) within 4 weeks prior to visit 1 (screening visit). * the patient has received any other systemically administered immunosuppressive drugs (other than glucocorticoids) within 8 weeks prior to visit 1. * the patient has received rituximab within 6 months prior to visit 1. * the patient has a history of organ transplantation.
intravenous cangrelor in high-bleeding risk patients undergoing percutaneous coronary intervention (icarus) registry

Conditions: Bleeding; Coronary Artery Disease; Myocardial Infarction

Summary: the study will investigate the prevalence of high bleeding risk (hbr) features and will compare the clinical outcomes of hbr and non-hbr patients among those undergoing percutaneous coronary intervention and receiving cangrelor infusion.

cangrelor administration is currently recommended by international guidelines in patients undergoing pci who are naïve to p2y12 inhibitors. these recommendations are based on the large cangrelor versus standard therapy to achieve optimal management of platelet inhibition (champion) program, which encompassed three randomized controlled trials (rcts) enrolling both chronic and acute coronary syndromes. consistently, the aforementioned studies showed the benefit of cangrelor in terms of ischemic events (mainly driven by a reduction of myocardial infarction - mi - and stent thrombosis - st) in the face of an increased rate of minor bleeding. however, those rcts were primarily focused on populations at considerable ischemic risk and with predictably low bleeding proneness, including young patients without bleeding risk features. in the contemporary practice, however, pci is increasingly frequent in patients at high risk of bleeding, who are not formally prevented from being administered with cangrelor by international guidelines and possibly necessitate powerful and rapid-onset platelet inhibition while undergoing complex percutaneous revascularization. the present registry was therefore conceived at the scope of collecting data on the use of cangrelor in high bleeding risk (hbr) patients undergoing contemporary pci. specifically, it will assess the frequency of hbr patients in a real-world cohort of individuals treated with cangrelor and will compare the clinical outcomes of hbr and non-hbr patients.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years 2. cangrelor administration during percutaneous coronary intervention for both acute and chronic coronary syndromes exclusion criteria: 1. cangrelor administration as a bridge to surgery

Keywords: percutaneous coronary intervention cangrelor high bleeding risk coronary artery disease acute myocardial infarction
kyoto congestive heart failure study

Conditions: Congestive Heart Failure; Heart Failure, Diastolic; Heart Failure, Systolic; Elderly Frail; Guideline Adherence

Summary: the purpose of this study is to investigate the patient characteristics, selection of treatment, and factors associated with clinical outcomes in japanese patients with acutely decompensated congestive heart failure.

congestive heart failure (chf) has been markedly increasing in japan due to the rapid aging of the society and the westernization of lifestyle that facilitates the development of coronary artery disease. the prognosis of patients with chf still remains poor, despite the recent advances in medical and surgical treatment. elderly heart failure patients with preserved ejection and multiple comorbidity may account for significant portion among chf patients in the real world clinical practice, however; most of previous prospective cohort studies excluded these patients. the kchf registry, an all-comer, prospective, multicenter registry, was designed to investigate all patients who admitted to the hospital due to acutly decompensated chf. the aim of this study was to clarify the patients characteristics , selection of treatment, and prognosis of patients with acutly decompensated chf in the real-world clinical practice in japan.

Eligibility criteria:
inclusion criteria: * all patients who admitted to the participating centers due to acutly decompensated chf defined by modified framingham criteria * patients who underwent heart failure treatment including intravenus drug exclusion criteria: * none

Keywords: congestive heart failure heart failure, diastolic heart failure, systolic elderly frail guideline adherence
effects of hypercapnia on emergence from general anesthesia under propofol

Conditions: Anesthesia, Intravenous; Anesthesia Recovery Period

Summary: hypercapnia derives increase of cerebral blood flow and cardiac output. it means that the rate of propofol elimination from the brain and the blood will be increased and the patient will awake more quickly. there has been no study about the effects of hypercapnia. the investigators will evaluate hypercapnia's effects on the recovery time from propofol anesthesia.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists physical status (asa ps) i-ii * age 20 - 60 years male and female * elective schedule with minor surgery under general anesthesia exclusion criteria: * body mass index (bmi) \>= 30 (kg/m2) * patient with pulmonary, cardiac, endocrinal, neuromuscular and neurological diseases or past history * patient with medication affecting on this study * patient with general anesthesia history within one month

Keywords: emergence hypercapnia hypocapnia propofol